Drug intelligence / Profile preview

Chuanqi Zhennaining Capsule

Development stage: Unknown
Lead developer: Wuhan Pharmaceutical Valley Technology Development
Administration: Oral

Overview

Chuanqi Zhennaining Capsule is a Traditional Chinese Medicine (TCM) candidate developed by Wuhan Pharmaceutical Valley Technology Development Co., Ltd. for the treatment of migraine, specifically those characterized by the blood stasis pattern. The formulation is a multi-herb extract designed to alleviate headache symptoms through mechanisms traditionally associated with invigorating blood and removing stasis. It has been evaluated in Phase 2 clinical trials in China (e.g., CTR20190325) as a randomized, double-blind, placebo-controlled treatment for adults with migraine.

Brand names: Chuanqi Zhennaining Capsule
Other names: 川芪镇脑宁胶囊

Beyond the preview

Go deeper on Chuanqi Zhennaining Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chuanqi Zhennaining Capsule.

Explore the full profile